JP2025516659A5 - - Google Patents

Info

Publication number
JP2025516659A5
JP2025516659A5 JP2024566662A JP2024566662A JP2025516659A5 JP 2025516659 A5 JP2025516659 A5 JP 2025516659A5 JP 2024566662 A JP2024566662 A JP 2024566662A JP 2024566662 A JP2024566662 A JP 2024566662A JP 2025516659 A5 JP2025516659 A5 JP 2025516659A5
Authority
JP
Japan
Prior art keywords
independently
nucleic acid
optionally substituted
oligonucleotide
heteroatoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024566662A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025516659A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/022142 external-priority patent/WO2023220440A1/en
Publication of JP2025516659A publication Critical patent/JP2025516659A/ja
Publication of JP2025516659A5 publication Critical patent/JP2025516659A5/ja
Pending legal-status Critical Current

Links

JP2024566662A 2022-05-12 2023-05-12 オリゴヌクレオチド組成物及びその方法 Pending JP2025516659A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263341407P 2022-05-12 2022-05-12
US63/341,407 2022-05-12
PCT/US2023/022142 WO2023220440A1 (en) 2022-05-12 2023-05-12 Oligonucleotide compositions and methods thereof

Publications (2)

Publication Number Publication Date
JP2025516659A JP2025516659A (ja) 2025-05-30
JP2025516659A5 true JP2025516659A5 (cg-RX-API-DMAC10.html) 2026-05-19

Family

ID=88731022

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024566662A Pending JP2025516659A (ja) 2022-05-12 2023-05-12 オリゴヌクレオチド組成物及びその方法

Country Status (7)

Country Link
US (1) US20250302995A1 (cg-RX-API-DMAC10.html)
EP (1) EP4522744A1 (cg-RX-API-DMAC10.html)
JP (1) JP2025516659A (cg-RX-API-DMAC10.html)
CN (1) CN119452084A (cg-RX-API-DMAC10.html)
AU (1) AU2023268503A1 (cg-RX-API-DMAC10.html)
CA (1) CA3253279A1 (cg-RX-API-DMAC10.html)
WO (1) WO2023220440A1 (cg-RX-API-DMAC10.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014010250A1 (en) 2012-07-13 2014-01-16 Chiralgen, Ltd. Asymmetric auxiliary group
EP3094728B1 (en) 2014-01-16 2022-03-09 Wave Life Sciences Ltd. Chiral design
CN117965536A (zh) 2015-07-22 2024-05-03 波涛生命科学有限公司 寡核苷酸组合物及其方法
MA46427A (fr) 2015-10-09 2018-08-15 Wave Life Sciences Ltd Compositions d'oligonucléotides et procédés associés
US11013757B2 (en) 2016-06-03 2021-05-25 Wave Life Sciences Ltd. Oligonucleotides, compositions and methods thereof
WO2018098264A1 (en) 2016-11-23 2018-05-31 Wave Life Sciences Ltd. Compositions and methods for phosphoramidite and oligonucleotide synthesis
WO2018237194A1 (en) 2017-06-21 2018-12-27 Wave Life Sciences Ltd. Compounds, compositions and methods for synthesis
CN111108096A (zh) 2017-09-18 2020-05-05 波涛生命科学有限公司 寡核苷酸制备技术
JP2021521140A (ja) 2018-04-12 2021-08-26 ウェイブ ライフ サイエンシズ リミテッドWave Life Sciences Ltd. オリゴヌクレオチド組成物及びその使用方法
CA3098624A1 (en) 2018-05-11 2019-11-14 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
AU2020241559A1 (en) 2019-03-20 2021-11-11 Wave Life Sciences Ltd. Technologies useful for oligonucleotide preparation
MX2021012981A (es) 2019-04-25 2022-01-18 Wave Life Sciences Ltd Composiciones de oligonucleotido y metodos de uso de las mismas.
WO2026077951A1 (en) 2024-10-07 2026-04-16 Vico Therapeutics B.V. Improved aon for rna editing
WO2026096688A1 (en) * 2024-10-30 2026-05-07 Wave Life Sciences Ltd. Oligonucleotide compositions and methods thereof
WO2026096689A1 (en) * 2024-10-30 2026-05-07 Wave Life Sciences Ltd. Oligonucleotide compositions and methods thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0821457D0 (en) * 2008-11-24 2008-12-31 Trillion Genomics Ltd Oligonucleotides
WO2018041973A1 (en) * 2016-09-01 2018-03-08 Proqr Therapeutics Ii B.V. Chemically modified single-stranded rna-editing oligonucleotides
EP3684378A4 (en) * 2017-09-19 2021-06-16 Children's National Medical Center GAPMERS AND THEIR USES IN THE TREATMENT OF MUSCLE DYSTROPHY
CA3154768A1 (en) * 2019-10-06 2021-04-15 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
US11434525B2 (en) * 2020-08-06 2022-09-06 Singular Genomics Systems, Inc. Spatial sequencing

Similar Documents

Publication Publication Date Title
JP2023548584A5 (cg-RX-API-DMAC10.html)
ES2376507T3 (es) An�?logos de �?cido nucleico bic�?clicos 6-disustituidos.
RU2115658C1 (ru) Гибридный олигонуклеотид, содержащий фосфоротиоатную и/или фосфородитиоатную связи, терапевтическая фармацевтическая композиция, способ ингибирования генной экспрессии
CN103003288B (zh) 具有修饰的亚基间键和/或端基的寡核苷酸类似物
KR100875003B1 (ko) 누클레오시드의 위치 변형에 의한 올리고누클레오티드 CpG 매개성 면역 자극의 조절
ES2320315T3 (es) Oligonucleotidos inmunoestimuladores.
ES2268736T3 (es) Moleculas de acido nucleico inmunoestimulantes.
CA2808233C (en) Aptamers to 4-1bb and their use in treating diseases and disorders
EP0680969B1 (de) Modifizierte Oligonukleotide, deren Herstellung sowie deren Verwendung
JP2023109824A (ja) GalNAc誘導体
JP2022551124A5 (cg-RX-API-DMAC10.html)
KR101807324B1 (ko) 다운 증후군 유전자에 대한 천연 안티센스 전사체의 억제에 의한 다운 증후군 유전자 관련된 질환의 치료
EP0710667A2 (de) Modifizierte Oligonukleotide, deren Herstellung sowie deren Verwendung
JP2010536792A (ja) テトラヒドロピラン核酸類似体
CN1118140A (zh) 为提高在酸性pH的稳定性而改性的低聚核苷酸
WO2011159328A1 (en) Methods of treatment using tlr7 and/or tlr9 inhibitors
JP2018162245A (ja) 三環式ヌクレオシド及びそれから調製されるオリゴマー化合物
KR101898177B1 (ko) 톨-유사 수용체 기반 면역 반응을 조절하기 위한 면역 조절 올리고누클레오티드 (iro) 화합물
TW201825103A (zh) 經修飾之寡核苷酸及使用方法
JP2017528441A5 (cg-RX-API-DMAC10.html)
JP2007510405A5 (cg-RX-API-DMAC10.html)
JP2018109015A (ja) 三環ヌクレオシドおよびこれらから調製したオリゴマー化合物
JP2011515357A5 (cg-RX-API-DMAC10.html)
JP2022552192A (ja) レチノイン酸誘導遺伝子iタンパク質に結合する核酸化合物
JP2007527246A (ja) ヒトil−12サイトカインファミリーに対するアプタマーおよび自己免疫疾患の治療剤としてのそれらの使用